Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totaling 263,542 shares, a decline of 65.6% from the June 15th total of 765,484 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average trading volume of 424,964 shares, the short-interest ratio is currently 0.6 days.

Cel-Sci Price Performance

CVM stock remained flat at $1.15 during trading on Wednesday. The company’s stock had a trading volume of 302,402 shares, compared to its average volume of 266,193. Cel-Sci has a one year low of $0.89 and a one year high of $13.48. The stock has a market capitalization of $20.10 million, a price-to-earnings ratio of -0.12 and a beta of 0.64. The company has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $3.34. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Institutional Trading of Cel-Sci

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC acquired a new stake in shares of Cel-Sci in the 4th quarter worth approximately $53,000. HRT Financial LP acquired a new position in shares of Cel-Sci during the fourth quarter valued at approximately $60,000. XTX Topco Ltd bought a new stake in Cel-Sci during the fourth quarter worth approximately $66,000. US Bancorp DE bought a new stake in Cel-Sci during the third quarter worth approximately $80,000. Finally, Renaissance Technologies LLC acquired a new stake in Cel-Sci in the fourth quarter worth approximately $81,000. 12.08% of the stock is currently owned by institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.